The clinical trial report, “Crohn's Disease (Regional Enteritis) - Global Clinical Trials Review, 2024" provides an overview of Crohn's Disease (Regional Enteritis) Clinical trials scenario. This report provides top line data relating to the clinical trials on Crohn's Disease (Regional Enteritis). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). The analyst Clinical Trial Reports are generated using the analyst’s proprietary database - Pharma - Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months
Reasons to Buy
- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level
- Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Table of Contents
- Report Guidance
- The analyst Clinical Trials Report Coverage
- Clinical Trials by Region
- Clinical Trials and Average Enrollment by Country
- Top Five Countries Contributing to Clinical Trials in Asia-Pacific
- Top Five Countries Contributing to Clinical Trials in Europe
- Top Countries Contributing to Clinical Trials in North America
- Top Five Countries Contributing to Clinical Trials in Middle East and Africa
- Top Five Countries Contributing to Clinical Trials in Central and South America
- Clinical Trials by G7 Countries: Proportion of Crohn's Disease (Regional Enteritis) to Gastrointestinal Clinical Trials
- Clinical Trials by Phase in G7 Countries
- Clinical Trials in G7 Countries by Trial Status
- Clinical Trials by E7 Countries: Proportion of Crohn's Disease (Regional Enteritis) to Gastrointestinal Clinical Trials
- Clinical Trials by Phase in E7 Countries
- Clinical Trials in E7 Countries by Trial Status
- Clinical Trials by Phase
- In Progress Trials by Phase
- Clinical Trials by Trial Status
- Clinical Trials by End Point Status
- Subjects Recruited Over a Period of Time
- Clinical Trials by Sponsor Type
- Prominent Sponsors
- Top Companies Participating in Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials
- Prominent Drugs
- Latest Clinical Trials News on Crohn's Disease (Regional Enteritis)
- Dec 18, 2024: Sanofi and Teva’s duvakitug meets primary endpoints in Phase IIb trial
- Dec 13, 2024: Takeda Provides an Update on Alofisel (Darvadstrocel)
- Dec 11, 2024: Nature Biotechnology | Generative Chemistry Enables Insilico to Develop Gut-Restricted PHD Inhibitors for Intestinal Barrier Repair & Immunomodulation
- Dec 02, 2024: Spyre Therapeutics begins dosing subjects in Phase I trials of anti-TL1A antibodies
- Nov 22, 2024: J&J eyes FDA approval for injection-based Tremfya in ulcerative colitis
- Nov 21, 2024: Palisade to Present Preclinical Results for PALI-2108 Demonstrating Engagement of Key Fibrotic Pathways of Crohn's Disease and Ulcerative Colitis (UC)
- Oct 28, 2024: Tremfya Is the First and Only Il-23 Inhibitor to Demonstrate Robust Results with a Fully Regimen in Both Induction and Maintenance in Crohn’s Disease
- Oct 28, 2024: Lilly’s Mirikizumab Is First and Only IL23p19 Antagonist for Both Ulcerative Colitis and Crohn’s Disease
- Oct 15, 2024: Celltrion Presents 2-year Post-hoc Analysis Findings for CT-P13 Sc Highlighting Dose Escalation as an Option for Managing Loss of Response in IBD
- Oct 14, 2024: Lilly Reports One-Year Histologic Outcomes in Phase 3 Study of Mirikizumab Compared to Ustekinumab for Crohn’s Disease
- Oct 14, 2024: Redx Presents Preclinical Data on RXC008, a Potential First-in-Class Therapy to Treat Fibrostenotic Crohn’s Disease, at the UEG Week
- Oct 10, 2024: Tremfya (Guselkumab) Demonstrates Impressive Results Across Biologic-Naïve and Biologic-Refractory Patients in Crohn’s Disease and Ulcerative Colitis
- Oct 03, 2024: Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn’s Disease
- Clinical Trial Profile Snapshots
- Appendix
- Abbreviations
- Definitions
- Research Methodology
- Secondary Research
- About the Analyst
- Contact the Publisher
- Source
- Crohn's Disease (Regional Enteritis) Therapeutics, Global, Clinical Trials by Region, 2024*
- Crohn's Disease (Regional Enteritis) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2024*
- Crohn's Disease (Regional Enteritis) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2024*
- Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2024*
- Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Europe, Top Five Countries, 2024*
- Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, North America, Top Countries, 2024*
- Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2024*
- Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2024*
- Proportion of Crohn's Disease (Regional Enteritis) to Gastrointestinal Clinical Trials, G7 Countries (%), 2024*
- Crohn's Disease (Regional Enteritis) Therapeutics, G7 Countries, Clinical Trials by Phase, 2024*
- Crohn's Disease (Regional Enteritis) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2024*
- Proportion of Crohn's Disease (Regional Enteritis) to Gastrointestinal Clinical Trials, E7 Countries (%), 2024*
- Crohn's Disease (Regional Enteritis) Therapeutics, E7 Countries, Clinical Trials by Phase, 2024*
- Crohn's Disease (Regional Enteritis) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2024*
- Crohn's Disease (Regional Enteritis) Therapeutics, Global, Clinical Trials by Phase, 2024*
- Crohn's Disease (Regional Enteritis) Therapeutics, Global, Clinical Trials In Progress by Phase 2024*
- Crohn's Disease (Regional Enteritis) Therapeutics, Global, Clinical Trials by Trial Status, 2024*
- Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Global, by End Point Status, 2024*
- Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2019-2023
- Crohn's Disease (Regional Enteritis) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2024*
- Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Global, Key Sponsors, 2024*
- Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2024*
- Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2024*
- Crohn's Disease (Regional Enteritis) Therapeutics, Global, Clinical Trials by Region (%), 2024*
- Crohn's Disease (Regional Enteritis) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2024*
- Crohn's Disease (Regional Enteritis) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2024*
- Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2024*
- Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2024*
- Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, North America, Top Countries (%), 2024*
- Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2024*
- Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2024*
- Proportion of Crohn's Disease (Regional Enteritis) to Gastrointestinal Clinical Trials, G7 Countries (%), 2024*
- Crohn's Disease (Regional Enteritis) Therapeutics, G7 Countries, Clinical Trials by Phase, 2024*
- Crohn's Disease (Regional Enteritis) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2024*
- Proportion of Crohn's Disease (Regional Enteritis) to Gastrointestinal Clinical Trials, E7 Countries (%), 2024*
- Crohn's Disease (Regional Enteritis) Therapeutics, E7 Countries, Clinical Trials by Phase, 2024*
- Crohn's Disease (Regional Enteritis) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2024*
- Crohn's Disease (Regional Enteritis) Therapeutics, Global, Clinical Trials by Phase (%), 2024*
- Crohn's Disease (Regional Enteritis) Therapeutics, Global, Clinical Trials In Progress by Phase, 2024*
- Crohn's Disease (Regional Enteritis) Therapeutics, Global, Clinical Trials by Trial Status, 2024*
- Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Global, by End Point Status, 2024*
- Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2019-2023
- Crohn's Disease (Regional Enteritis) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2024*
- Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Global, Key Sponsors, 2024*
- Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2024*
- Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2024*
- The analyst Methodology
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Takeda Pharmaceutical Co Ltd
- AbbVie Inc
- Johnson & Johnson
- Pfizer Inc
- UCB SA
- Thermo Fisher Scientific Inc
- Bristol-Myers Squibb Co
- Merck & Co Inc
- C. H. Boehringer Sohn AG & Co KG
- The Alimentiv Health Trust
